Skip to main content

Pharmaceutical R&D AI: Protecting Drug Discovery Data from LLM Exposure

Pharmaceutical R&D teams usually worry about two different leak paths at once: patient-linked clinical research data and proprietary discovery context that should not leave an approved compute boundary. Keeptrusts helps most when you separate those risks and govern both at the gateway: use healthcare policies to protect trial and medical data, use route and provider controls to constrain where sensitive research traffic can run, and make every request auditable so research, security, and compliance teams can review the exact boundary that production traffic followed.

Use this page when​

  • You are using LLMs for protocol drafting, trial summarization, literature synthesis, or research copilot workflows.
  • You need patient-linked study data protected before it can reach an upstream provider.
  • You want a governed route for R&D teams instead of unmanaged model access.

Primary audience​

  • Primary: Technical Leaders
  • Secondary: Technical Engineers, Research platform owners

The problem​

Drug discovery and clinical development teams tend to have mixed data in the same workflow. One prompt may contain a de-identified target summary. The next may include a trial note with dates, subject references, or investigator comments. Another may discuss unpublished assay results or internal program strategy. From a governance perspective, that mix is dangerous because teams often apply one oversimplified rule to all of it.

The first bad rule is “research data is not patient data, so standard enterprise AI access is fine.” That ignores how often trial operations, translational medicine, pharmacovigilance, and protocol design workflows include patient-linked content or health information.

The second bad rule is “just use a zero-retention provider and everything is solved.” Zero retention matters, but it is not enough. You still need to decide whether certain content should be blocked, de-identified, escalated, or confined to a narrower route. Provider posture is part of the control, not the whole control.

The third bad rule is “the application can decide what is sensitive.” That rarely scales in pharma environments where teams adopt AI across clinical operations, biomarker analysis, medical writing, and portfolio review at different speeds. Without a central gateway, each team ends up creating its own informal sensitivity logic, which is exactly how governance drift begins.

Keeptrusts gives you a better operating model. It cannot infer every kind of drug discovery intellectual property automatically, and you should not claim that it does. What it can do reliably is enforce provider boundaries, log route decisions, apply PHI and healthcare data controls to patient-linked research traffic, and create a consistent policy surface for assistants that operate inside a pharma environment.

That distinction is important. For subject-level or medically linked content, HIPAA PHI Detector, Healthcare Compliance, and the healthcare reference guides such as Healthcare (HIPAA), Healthcare (EU GDPR), and Secure Healthcare AI are directly relevant. For non-patient R&D IP, the safer control is route isolation: approved providers only, approved users only, and a full event trail.

The solution​

The safest pharmaceutical AI architecture uses separate trust assumptions for different workloads.

For subject-level or medically linked workflows, treat the content like healthcare data first. Use hipaa-phi-detector and pii-detector to de-identify or block patient-linked inputs. Use data-routing-policy so the route cannot quietly fall back to a non-approved provider. Use audit-logger so research compliance teams can prove what happened.

For purely proprietary discovery analysis, the key control is not a magical “drug discovery detector.” It is a route that only approved research systems can access and that only approved provider targets can use. In practice, many pharma teams handle their most sensitive discovery traffic by routing it to self-hosted or tightly controlled provider targets while still using Keeptrusts for auditability and access enforcement.

Then add healthcare-compliance where the assistant may generate clinical or quasi-clinical language. R&D assistants drift quickly from literature synthesis into interpretation. Once that happens, disclaimers and blocked medical phrases matter, especially when research and medical affairs teams are sharing the same tooling.

Implementation​

This example assumes a pharma route that allows de-identified research traffic through an approved provider set while protecting patient-linked study content at the gateway.

pack:
  name: pharma-r-and-d-governed-route
  version: 1.0.0
  enabled: true

providers:
  targets:
    - id: local-research-model
      provider: ollama
      model: llama3.1:70b
      base_url: http://localhost:11434
    - id: openai-zdr
      provider: openai
      model: gpt-5.4-mini-mini
      secret_key_ref:
        env: OPENAI_API_KEY
      data_policy:
        zero_data_retention: true
        training_opt_out: true
        retention_days: 0

policies:
  chain:
    - prompt-injection
    - rbac
    - hipaa-phi-detector
    - pii-detector
    - data-routing-policy
    - healthcare-compliance
    - audit-logger

policy:
  prompt-injection: {}

  rbac:
    deny_if_missing:
      - X-User-ID
      - X-User-Role

  hipaa-phi-detector:
    action: redact
    mode: hipaa_18
    safe_harbor_method: true

  pii-detector:
    action: redact
    healthcare_mode: true

  data-routing-policy:
    require_zero_data_retention: true
    on_no_compliant_provider: block
    log_provider_selection: true

  healthcare-compliance:
    blocked_patterns:
      - prescribe
      - diagnose you with
    required_disclaimers:
      - This output is research support only and is not medical advice.
    fda_class: II

  audit-logger:
    immutable: true
    retention_days: 2555

The main design choice here is deliberate. If the route handles patient-linked study content, hipaa-phi-detector and pii-detector run before provider routing. That means research teams do not need to remember which prompt fragments are safe. The gateway decides.

data-routing-policy then prevents the system from using a provider target that does not meet the route’s retention requirements. If you want a stricter posture for certain programs, create a separate route whose only target is the self-hosted provider. That is often the right answer for unpublished discovery strategy or especially sensitive internal programs.

Use a small validation loop during rollout:

kt policy lint --file ./pharma-r-and-d-governed-route.yaml
kt gateway run --policy-config ./pharma-r-and-d-governed-route.yaml --port 41002
kt events tail --policy hipaa-phi-detector
kt events tail --policy data-routing-policy

That gives you direct evidence that patient-linked content is governed and that provider selection followed the approved route.

Results and impact​

For pharmaceutical organizations, the biggest gain is boundary clarity. Research teams know which assistants are suitable for subject-level content, which routes are limited to approved providers, and which workflows require a tighter compute boundary. Security teams know where to audit. Compliance teams know what event stream to sample. Platform teams stop rebuilding one-off controls in notebook tools, internal portals, and document helpers.

This also reduces policy sprawl. Instead of every research product deciding independently how to handle clinical notes or investigator comments, the governed route becomes the standard entry point. Teams can still tune routes for different programs, but they do it with declared policy packs rather than hidden application branches.

Most importantly, it prevents a common governance failure in pharma AI adoption: assuming that all “research” traffic has the same sensitivity. It does not. Subject-level data, medical writing drafts, and proprietary program strategy do not deserve the same route by default. A gateway can enforce that distinction consistently.

Key takeaways​

  • In pharmaceutical AI, separate patient-linked health data from proprietary research IP and govern both explicitly.
  • Use healthcare policies for clinical or subject-level data, and use provider and route controls for discovery-boundary enforcement.
  • Do not claim automatic detection of every kind of drug discovery secret; route isolation is the safer documented control.
  • Keep audit-logger in the chain so research compliance reviews are evidence-based.
  • Cross-reference the healthcare source docs for the patient-data side of pharma AI: Healthcare (HIPAA), Healthcare (EU GDPR), HIPAA PHI Detector, Healthcare Compliance, and Secure Healthcare AI.

Next steps​